Jeff Hargroves was appointed Director of Cingulate Inc. As of November 6, 2026, Cingulate Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 2, 2026 to July 14, 2026, naming 2 appointments (Form 8-K, July 14, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Cingulate Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Jeff Hargroves · Role: Director · 8-K, 2026-07-14
- · In / out: In · Person: Jeff Hargroves · Role: Director · 8-K, 2026-05-19
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-04-02
Cingulate Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-02 to 2026-07-14. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Cingulate Inc. files it.
Also on the record for Cingulate Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| March 26, 2026 | Stake report, Schedule 13D/A, by Falcon Creek Capital Advisor LLC | 28.5% of the class | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13D, by Falcon Creek Capital Advisor LLC | 19.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Cingulate Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Cingulate Inc. and the records around it.
Cingulate Inc. elsewhere on the record
Watch Cingulate Inc.
Get an email when Cingulate Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cingulate Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Cingulate Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cingulate Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-14 | In | Director | 8-K, 2026-07-14 | ||
| 2026-05-19 | In | Director | 8-K, 2026-05-19 | ||
| 2026-04-02 | Reported | not named in the filing | 8-K, 2026-04-02 |
Who leads Cingulate Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Jeff Hargroves, appointed (filed 2026-07-14).
New leaders reset buying decisions — get the Full Report on Cingulate Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Cingulate Inc., with the record behind each one.
Find candidates like Director at Cingulate Inc.Every change, in the filing's words
Appointed: Jeff Hargroves, Director
The Board appointed Jeff Hargroves as the lead independent director of the Board.
- Equity Plan Amendment At the Cingulate Inc. (the "Company") 2026 Annual Meeting of Stockholders held on July 9, 2026 (the "Annual Meeting"), the Company's stockholders approved Amendment No. 3 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan (the "Equity Plan") to increase the number of shares of common stock authorized for issuance thereunder by 625,000 shares (the "Amendment").
- The board of directors of the Company had previously approved the Amendment, subject to stockholder approval, and the Amendment became effective upon such stockholder approval.
- Changes to Board Structure On the date of the Annual Meeting, the Company's Board of Directors (the "Board") reduced the size of the Board to five (5) directors and appointed Shane Schaffer, the Company's Chief Executive Officer, as the chairman of the Board.
- The Board also appointed Zhanpeng "Frederick" Jiang as the chairman of the Audit Committee of the Board and Mr. Hargroves as the chairman of the Nominating and Corporate Governance Committee of the Board.
Appointed: Jeff Hargroves, Director
On May 18, 2026, the Board accepted Mr. Hargroves resignation and immediately thereafter appointed Mr. Hargroves as a Class II director.
- The current Class II directors of the Board of Directors (the "Board") of Cingulate Inc. (the "Company"), Jeff Ervin and Jay Roberts, will not seek re-election when their respective terms expire at the Company's 2026 Annual Meeting of Stockholders in an effort to reduce the size of the Board.
- On the date of the Annual Meeting, the Board intends to reduce the size of the Board to five (5) directors and appoint a new chairman.
- In order to effect the provision of our certificate of incorporation that provides that each class must consist, as nearly as may be practicable, of one-third of the total number of directors constituting the entire Board, Jeff Hargroves has agreed to resign from the Board as a Class I director solely for the purpose of being re-appointed to the Board as a Class II director.
- The Board also nominated Mr. Hargroves to stand for election at this year's Annual Meeting.
- Following this re-appointment, the Class I directors consist of Peter Werth and Frederick Jiang.
Reported
Following the appointment of Mr. Jiang, the Class I directors will consist of Peter Werth, Jeff Hargroves and Mr. Jiang.
- Mr. Jiang was appointed to serve as a member of the Audit Committee of the Board.
- Following the appointment of Mr. Jiang, the Audit Committee will consist of Jeffrey S. Ervin, as chairman, John A. Roberts, Bryan Lawrence, Mr. Hargroves and Mr. Jiang.
- Mr. Jiang was appointed to serve as a member of the Compensation Committee of the Board.
- Following the appointment of Mr. Jiang, the Compensation Committee will consist of Mr. Lawrence, as chairman, Mr. Ervin, Mr. Roberts, Mr. Hargroves and Mr. Jiang.
- Mr. Jiang was also appointed to serve as a member of the Nominating and Corporate Governance Committee of the Board.
- Following the appointment of Mr. Jiang, the Nominating and Corporate Governance Committee will consist of Mr. Ervin, as chairman, Mr. Lawrence, Mr. Roberts, Mr. Hargroves and Mr. Jiang.
- The Board has determined that Mr. Jiang is independent as defined in Listing Rule 5605 of the Nasdaq Stock Market LLC for purposes of serving on the Board.
- Pursuant to the Company's Non-Employee Director Compensation Program (the "Director Compensation Program"), Mr. Jiang was granted an option to purchase 15,000 shares of the Company's common stock (the "Option").
Tools for this story
Each opens in a new tab, filled in for Cingulate Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.